Aptamer Group PLC Block listing Interim Review

RNS Number : 6445B

Aptamer Group PLC

27 August 2024

 

27 August 2024

 

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

 

Block Listing Interim Review

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer^® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:

 

 

Name of Company	Aptamer Group plc
Name of Scheme	The Aptamer Group EMI Share Option Scheme
Period of Return (from/to)	25 February 2024 to 24 August 2024
Number and class of securities not issued at the start of the period under the scheme	1,666,477 Ordinary Shares
Number of securities issued under the scheme during the period	0
Balance under the scheme of securities not yet issued at the end of the period	1,666,477 Ordinary Shares
Number and class of securities originally admitted and the date of admission	2,063,200 Ordinary Shares on 25 February 2022
Name of contact and telephone number	Andrew Rapson [phone]

 

 

 

 

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc Dr Arron Tolley	[phone]
SPARK Advisory Partners Limited - Nominated Adviser   Andrew Emmott / Adam Dawes	[phone]
Turner Pope Investments (TPI) Limited - Broker   James Pope / Andrew Thacker	[phone]

 

 

About Aptamer Group plc

 

Aptamer develops custom affinity binders through its proprietary Optimer^® platform to enable new approaches in therapeutics, diagnostics, and research applications.  The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

 

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative.  The global affinity ligand market is currently worth over $170 billion.  Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

 

Aptamer has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses.  Through the unique Optimer technology and processes, scientists and collaborators can make faster, more informed decisions that support discovery and development across the Life Sciences.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

BLRXXLFLZVLZBBX